Characteristics of the Study Sample, by Cohort.

<p>ART = antiretroviral therapy; HMO = health maintenance organization; POS = point of service; PPO = preferred provider organization; SD = standard deviation.</p>a<p>Evaluated in the 6-month pre-index period.</p

Adjusted Rate of Hospitalization, by Cohort.

<p>Adjusted Rate of Hospitalization, by Cohort.</p

Predictors of Hospitalization, Using Multivariate Logistic Regression and Controlling for Treatment Regimen Received.

<p>CI = confidence interval; HMO = health maintenance organization; POS = point of service; PPO = preferred provider organization.</p

Predictors of Hospitalization, Using Multivariate Logistic Regression and Controlling for Adherence Threshold.

<p>CI = confidence interval; HMO = health maintenance organization; POS = point of service; PPO = preferred provider organization.</p

Sample Selection Flow Chart.

<p>Sample Selection Flow Chart.</p

Frequency of Hospitalizations, by Cohort^a.

<p>Frequency of Hospitalizations, by Cohort^a.</p

Adherence to ART Regimens, by Cohort.

<p>ART = antiretroviral therapy; MPR = medication possession ratio; SD = standard deviation.</p>a<p><i>P</i> values calculated from Students t-test for mean MPR, Wilcoxon rank sum tests for median MPR, and chi-square for distribution by MPR threshold.</p

1-, 3-, 5- and 7-Year Survival Rates Post-Diagnosis, by MPN Subtype.

<p>ET = essential thrombocythemia, PV = polycythemia vera, MF = myelofibrosis,</p

Kaplan-Meier Survival Estimates, by MPN Subtype.

<p>ET = essential thrombocythemia, PV = polycythemia vera, MF = myelofibrosis.</p

Patient Characteristics, by MPN Subtype.

<p>* Per SEER-Medicare privacy rules, cell sizes <11 have been supressed, requiring collapsed reporting of “Other” race as follows: ET: “Other” includes North American Native and Other race/ethnicity; PV: “Other” includes North American Native and Other race/ethnicity; MF: “Other” includes Asian, Hispanic, North American Native, and Other race/ethnicity.</p